Antiviral Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Growth Factors of Antiviral drugs Market

The antiviral drugs market size was valued at USD 36.18 billion in 2018, and the market is now projected tgrow tUSD 58.84 billion by 2026, exhibiting a CAGR of 4.0% during the forecast period of 2019-2026.

The COVID-19 pandemic has both positive and negative effects on the development of a market for antiviral drugs. On one hand, the urgency of the problem in the context of SARS-CoV-2 distribution determined the growth of the quantity of publications, experiments, and clinical trials concerning the repurposing of drugs or developing new ones. This led thigh demand of antiviral drugs as had never been seen before in the world. On the other hand, it upset customer relations and supply systems, and demand for healthcare reorientation tCOVID-19 undermined production and distribution of existing antiviral drugs used in other diseases like HIV, hepatitis, and influenza. As the diseases stabilised and became chronic, the emphasis moved tantiviral drugs, broad-spectrum and combination therapies. This hindered the antiviral drugs market growth.

Different main pharmaceutical companies are increasingly involved in the discovery of antiviral agents. This was welcome by the introduction of blockbuster drugs Biktarvy by Gilead Science and Triumeq by GlaxoSmithKline. Thus, the increasing use of such large-volume agents and the enhancement of their delivery by the manufacturers would drive the antiviral market revenue throughout the 2019 t2026 period. Biktarvy launched in February 2018 and it is intended ttarget the populations that are affected by HIV in the world. Of those, 21 million are on antiretroviral therapy which enable the immune system tregain some power. These factors drive the antiviral drugs market share.

An active trend is the production of broad-spectrum antivirals, which can act on one or several viruses or entire virus families. These drugs have been developed tcombat the new viruses and lower the demand for pathogen-targeted medicines. The exciting developments in genomic and structural biology are allowing the discovery of conserved viral targets, while the improved drug delivery systems, including nanoparticles, are the factor boosting efficacy. This trend has been on the rise owing tincreasing concern about pandemic and establishment of treatments capable of handling new or mutated virus strains.

Comprehensive Analysis of Antiviral drugs Market

The antiviral drugs market is responding quite an unprecedented rate of growth because of its market segmentation. This indicators growth in different regions by substituting the major forces of supply and demand which define the shape of local pharmacy benefit management market. Therefore, they are logically divided int3 Segments, By Drug Class Analysis, By Disease Indication Analysis and By Distribution Channel Analysis. The antiviral medication market has been classified based on the drug classification as protease inhibitors, polymerase inhibitors, integrase inhibitors, combination medicines, reverse transcriptase inhibitors and others. Depending on the disease indication, the antiviral therapeutics market is segmented as hepatitis, human immunodeficiency virus (HIV), influenza, and others. According tthe sales channel, the global market is segmented into: hospital pharmacy, retail pharmacy, and online channel. Major factors forcing the growth of the hospital pharmacy segment is government polices aimed at viral diseases particularly government aid topen government aided hospital pharmacy policies on reimbursement and strengthening the supply chain of the key manufacturers.

The North American region was valued at USD 13.9 billion in 2018. This is due tthe increased concentration of important pharma majors in the U.S., rising incidences of infections, including HIV in the region, and the clearance by USFDA tlaunch premiere and effective therapies in North America. The growth in Europe in the coming years is expected tbe quite remarkable due tthe favourable reimbursement practices for antiviral therapy and key players in the development of antiviral medicine as HIV.

Gilead Sciences (U.S.), GlaxoSmithKline (U.K.), AbbVie, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Janssen Pharmaceuticals, Inc. (U.S.), Mylan N.V. (U.S.), and Novartis AG (Switzerland) are significant players in the pharmaceutical market. They are the key player that ensures the industry's success while still having tkeep pace with their innovation in product and services. They offer a competitive zone that incites the growth of technologies and quality assurance. They operate on a global scale and have a wide range of product lines ensuring that the market players compete on a fair playing field bringing in innovations that result in the market's evolution.

In January 2021, iiV Healthcare, a global HIV specialist organisation that is majority-owned by GlaxoSmithKline and Pfizer in partnership with Pfizer Inc said that it got clearance for Cabenuva from the US Food and Drug Administration (FDA). The drug enables the treatment tbe administered for only 12 days in a year unlike other 365 days in a year.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2015-2026

Base Year 2018

Forecast Period 2019-2026

Historical Period 2015-2017

Unit Value (USD million)

Segmentation By Drug Class

Protease Inhibitors

Polymerase Inhibitors

Integrase Inhibitors

Reverse Transcriptase Inhibitors

Combination Drugs

Others

By Disease Indication

Hepatitis

Human Immunodeficiency Virus (HIV)

Influenza

Others

By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Channel

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East and Africa (South Africa, GCC, and Rest of Middle East & Africa)